{"organizations": [], "uuid": "106d0c1d8e471d7723b5fb2c8a1c6586cf803d19", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/juno-ma-celgene/celgene-in-talks-to-buy-juno-therapeutics-wsj-idUSL3N1PB5H3", "country": "US", "domain_rank": 408, "title": "Celgene in talks to buy Juno Therapeutics - WSJ", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-17T06:09:00.000+02:00", "replies_count": 0, "uuid": "106d0c1d8e471d7723b5fb2c8a1c6586cf803d19"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/juno-ma-celgene/celgene-in-talks-to-buy-juno-therapeutics-wsj-idUSL3N1PB5H3", "ord_in_thread": 0, "title": "Celgene in talks to buy Juno Therapeutics - WSJ", "locations": [], "entities": {"persons": [{"name": "ankur banerjee", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "juno therapeutics inc", "sentiment": "negative"}, {"name": "celgene corp", "sentiment": "negative"}, {"name": "celgene", "sentiment": "negative"}, {"name": "wsj", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Celgene Corp is in talks to buy Juno Therapeutics Inc, the Wall Street Journal reported, citing sources familiar with the matter. ( on.wsj.com/2EMlysO )\nShares of Juno, which has a market value of $5.57 billion, were up 36 percent at $62.50 in extended trading on Tuesday.\nThe WSJ report comes days after Celgene said it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance. (Reporting by Ankur Banerjee in Bengaluru)\n ", "external_links": ["http://on.wsj.com/2EMlysO", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T06:09:00.000+02:00", "crawled": "2018-01-17T19:46:45.005+02:00", "highlightTitle": ""}